Abstract
The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 5438-5440 |
| Number of pages | 3 |
| Journal | Clinical Cancer Research |
| Volume | 25 |
| Issue number | 18 |
| DOIs | |
| State | Published - Sep 15 2019 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Nivo-lution in mesothelioma. / Mansfield, Aaron; Zauderer, Marjorie G.
In: Clinical Cancer Research, Vol. 25, No. 18, 15.09.2019, p. 5438-5440.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Nivo-lution in mesothelioma
AU - Mansfield, Aaron
AU - Zauderer, Marjorie G.
PY - 2019/9/15
Y1 - 2019/9/15
N2 - The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.
AB - The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.
UR - http://www.scopus.com/inward/record.url?scp=85072234485&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85072234485&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-19-1836
DO - 10.1158/1078-0432.CCR-19-1836
M3 - Article
C2 - 31315884
AN - SCOPUS:85072234485
VL - 25
SP - 5438
EP - 5440
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 18
ER -